Semax

From Wikipedia, the free encyclopedia - View original article

Met-Glu-His-Phe-Pro-Gly-Pro
Semax structure.png
Systematic (IUPAC) name
(2S)-1-[2-([(2S)-1-[(2S)-2-([2-([(2S)-2-([(2S)-2-amino-4-methylsulfanylbutanoyl]amino)-5-hydroxy-5-oxopentanoyl]amino)-3-(1H-imidazol-5-yl)propanoyl]amino)-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino)acetyl]pyrrolidine-2-carboxylic acid
Clinical data
Legal statusUnscheduled
Identifiers
CAS number4037-01-8
80714-61-0 (free base)
ATC codeNone
PubChemCID 122178
Chemical data
FormulaC37H51N9O10S 
Mol. mass813.92 g/mol
 
Jump to: navigation, search
Met-Glu-His-Phe-Pro-Gly-Pro
Semax structure.png
Systematic (IUPAC) name
(2S)-1-[2-([(2S)-1-[(2S)-2-([2-([(2S)-2-([(2S)-2-amino-4-methylsulfanylbutanoyl]amino)-5-hydroxy-5-oxopentanoyl]amino)-3-(1H-imidazol-5-yl)propanoyl]amino)-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino)acetyl]pyrrolidine-2-carboxylic acid
Clinical data
Legal statusUnscheduled
Identifiers
CAS number4037-01-8
80714-61-0 (free base)
ATC codeNone
PubChemCID 122178
Chemical data
FormulaC37H51N9O10S 
Mol. mass813.92 g/mol

Semax is a drug produced and prescribed mostly in Russia and Ukraine for a broad range of disorders but predominantly for its purported nootropic, neuroprotective and neurorestorative properties. Semax is a heptapeptide, synthetic analogue of an ACTH (4-10) fragment of corticotropin, of the following structure: Met-Glu-His-Phe-Pro-Gly-Pro. Based on one of the endogenous neuropeptides regulating the functions of the central nervous system. The compound has not been evaluated by the FDA. It is unscheduled in the US and legal to import by private citizens for personal use.[1][2]

Semax has undergone extensive study in Russia and is on the Russian “List of Vital & Essential Drugs” approved by the RF Government on December 7, 2011 N 2199, ATC code N06BX.[3] Medical uses for Semax include treatment of strokes, TIA (Transient Ischemic Attack), memory and cognitive disorders, peptic ulcers, optic nerve disease and to boost the immune system.[1][1][4][5][6]

References[edit]

  1. ^ a b c Institute of Molecular Genetics, Russian Academy of Sciences website (http://old.img.ras.ru/semax1-e.htm)
  2. ^ DEA List of Controlled Substances
  3. ^ Russian List of Vital & Essential Drugs 2199 (http://semax.ru/filemanager/download/26/)
  4. ^ Kurysheva, NI; Shpak, AA; Ioĭleva, EE; Galanter, LI; Nagornova, ND; Shubina, NIu; Shlyshalova, NN (2001). "Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone". Vestnik oftalmologii 117 (4): 5–8. PMID 11569188. 
  5. ^ Ivanikov, IO; Brekhova, ME; Samonina, GE; Myasoedov, NF; Ashmarin, IP (2002). "Therapy of peptic ulcer with semax peptide". Bulletin of experimental biology and medicine 134 (1): 73–4. doi:10.1023/A:1020621124776. PMID 12459874. 
  6. ^ Korneev, EA; Kazakova, TB (1999). "Current approaches to the analysis of the effects of stress on metabolic processes in cells of the nervous and immune systems". Med. Immunology 1 (1–2): 17–22.